









Markets
/
Stocks
/
nasdaq-atxs
/

Astria Therapeutics Inc

ATXS

12.510USD

+0.080+0.64%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

705.99MMarket Cap

LossP/E TTM



Astria Therapeutics Inc

12.510

+0.080+0.64%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Astria Therapeutics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Astria Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

39 / 407

Overall Ranking

134 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Hold

Current Rating

25.833

Target Price

+106.50%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Astria Therapeutics Inc Highlights

StrengthsRisks

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -6.20, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 57.81M shares, decreasing 16.85% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.19K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 8.21, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.21

Change



Financials

8.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.70

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.33

Key Metrics

Free cash flow

No Data

Astria Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.17, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.20, which is -67.79% below the recent high of -2.00 and -11.29% above the recent low of -6.90.

Score

Industry at a Glance

Previous score

6.17

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 6.75, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Astria Therapeutics Inc is 22.50, with a high of 49.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

6.75

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Hold

Current Rating

25.833

Target Price

+106.50%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Astria Therapeutics Inc

ATXS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 9.37, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 14.12 and the support level at 9.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.38

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.290

Neutral

RSI(14)

72.564

Buy

STOCH(KDJ)(9,3,3)

62.228

Neutral

ATR(14)

0.234

High Vlolatility

CCI(14)

-7.358

Neutral

Williams %R

31.783

Buy

TRIX(12,20)

1.630

Sell

StochRSI(14)

14.940

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

12.440

Buy

MA10

12.495

Buy

MA20

12.118

Buy

MA50

9.306

Buy

MA100

7.837

Buy

MA200

6.738

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 102.43%, representing a quarter-over-quarter decrease of 3.82%. The largest institutional shareholder is The Vanguard, holding a total of 2.52M shares, representing 4.47% of shares outstanding, with 5.46% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

6.49M

Vestal Point Capital, LP

4.52M

+8.18%

Forbion Capital Partners

4.11M

+7.46%

Fidelity Management & Research Company LLC

3.66M

-23.93%

BlackRock Institutional Trust Company, N.A.

3.18M

-6.53%

Fidelity Institutional Asset Management

2.80M

+31.52%

TCG Crossover Management, LLC

2.76M

The Vanguard Group, Inc.

Star Investors

2.52M

-4.41%

VR Adviser, LLC

2.46M

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 2.77, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.08. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.